Denali Therapeutics announces achievement of RIPK1 milestone for Phase 2 trial

Denali Therapeutics (DNLI) announced that its partner Sanofi (SNY) has commenced dosing in a Phase 2 study of SAR443820 in individuals with multiple sclerosis. SAR443820 is a central nervous system-penetrant investigational small molecule inhibitor of RIPK1. Under the collaboration agreement, Denali will receive a milestone payment of $25 million from Sanofi for initiation of the Phase 2 study with SAR443820 in multiple sclerosis. Denali is entitled to receive additional development and regulatory milestone payments. Denali will share profits and losses equally with Sanofi for CNS-penetrant products sold in the United States and China, and Denali is entitled to receive royalties on net sales for CNS-penetrant products sold outside of the United States and China.